Puma Bio stock: buy or sell?
December 6th, 2019
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care.
Should I buy Puma Bio stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Puma Bio stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Puma Bio stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we collected 10 ratings published for PBYI stock in the last 30 days. The general sentiment of these ratings is bearish for PBYI stock, with 4 negative ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-12||JPMorgan Chase & Co.||n/a||Sell|
|2019-5-29||Goldman Sachs Group||n/a||Neutral|
|2019-5-10||JPMorgan Chase & Co.||n/a||Underweight|
Puma Bio stock analysis
After sliding a hair-raising -20.30% yesterday, Puma Bio closed today at $7.88 and climbed an astounding 5.91%.
After sliding a hair-raising -20.30% yesterday, Puma Bio closed today at $7.88 and climbed an astounding 5.91%. Since price and SMA100d lines crossed down on Tuesday, PBYI fell $-2.85 per share (-26.56%).
Puma Bio collapsed a bloodcurdling -16.97% this week. By mid November PBYI skyrocketed a dazzling 13.10% in just one week.
Since price and 40-weeks moving average lines crossed down early April, PBYI fell $-27.58 per share (-77.78%). Stocks under the 200 days moving average line are usually not recommended for average traders.
Puma Bio stock price history
Puma Bio IPO was on April 24th, 2012 at $13.00 per share1. Since then, PBYI stock declined a -39.40%, with a yearly average of -5.60%.
1: Adjusted price after possible price splits or reverse-splits.
Puma Bio stock historical price chart
PBYI stock reached 52-week highs on March at $43.90, and all-time highs 2014-08-26 with a price of 279.37.
Puma Bio stock price target is $29.40Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' PBYI stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 9 price forecasts for PBYI stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-12||JPMorgan Chase & Co.||Reiterates||n/a||$13.00||-|
|2019-5-29||Goldman Sachs Group||Lowers Target||$29.00||$24.00||-17.2%|
|2019-5-10||JPMorgan Chase & Co.||Lowers Target||$27.00||$19.00||-29.6%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Puma Bio didn't meet the estimates of the analysts and reported an awful EPS of $-0.80 per share when experts were expecting $-0.92.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a dazzling gain of 806.60% to $250.99 M USD. When comparing 2018 vs 2017, similarly, profit margin (that is, the net income divided by revenues) rocketed a 1,009.31% to -45.25%.
|2017||$28 M||-||$-291.96 M-1054.6%||-|
|2018||$251 M||806.60%||$-113.58 M-45.3%||-61.10%|
Quarterly financial resultsPuma Bio posted $71.08 million in revenues for 2018-Q4, a 13.49% up compared to previous quarter. Reported quarter income marked $-30.70 million with a profit margin of -43.18%. Profit margin plunged a -20.51% compared to previous quarter when profit margin was -22.67%. When comparing sales to same quarter last year, Puma Biotechnology sales marked an outstanding increase and boosted a 228.95%. Looking back to recent quarterly results, Puma Biotechnology posted 2 negative quarters in a row.
|2017-Q3||$6 M||-||$-77.18 M-1269.4%||-|
|2017-Q4||$22 M||255.39%||$-64.08 M-296.5%||-16.98%|
|2018-Q1||$67 M||207.83%||$-24.35 M-36.6%||-62.01%|
|2018-Q2||$51 M||-23.68%||$-44.34 M-87.3%||82.11%|
|2018-Q3||$63 M||23.37%||$-14.20 M-22.7%||-67.97%|
|2018-Q4||$71 M||13.49%||$-30.70 M-43.2%||116.15%|
Puma Bio ownershipWhen you are planning to buy shares of a stock, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Puma Bio, 13.44% of all outstanding shares are owned by its staff.
Bearish positions for PBYI stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$307.0 M||$16.1 M||$113.3 B||$210.3 B|
|Total shares||39.0 M||19.7 M||2,490.0 M||5,530.0 M|
|Float shares||30.1 M||14.4 M||2,450.0 M||5,530.0 M|
|- Institutional holdings (%)||100.9%||8.1%||11.0%||76.2%|
|- Insider holdings (%)||13.4%||16.9%||0.0%||0.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%|
Puma Bio summary
|Friday, December 6th, 2019|
|Day range||$7.68 - $8.14|
|Average true range||$0.85|
|50d mov avg||$8.23|
|100d mov avg||$9.38|
|200d mov avg||$17.36|
Puma Bio performanceStocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. For Puma Biotechnology, the comparison is made against Dare Bioscience, GlaxoSmithKline and Pfizer.